Abbott Laboratories has undergone a subtle but important shift in valuation following its latest earnings release, with the recent price action highlighting both the source of near-term pressure and the underlying stability of the broader business. Looking at the move in the P/E ratio, now sitting around 16, the compression tells a consistent story. The…